A drug called elraglusib doubled one-year survival rates in people with advanced pancreatic cancer when combined with chemotherapy—42% survived one year compared to 22% on chemotherapy alone, according to a trial published in Nature Medicine on April 14. Pancreatic cancer kills most patients quickly because tumors hide inside a dense, fibrous barrier that blocks chemotherapy and the immune system; elraglusib dissolves that barrier by suppressing a protein called GSK-3 beta. The trial tested 286 patients with metastatic disease, and median survival stretched from 7.2 months to 10.1 months—meaningful gains but still short survival windows reflect pancreatic cancer's severity.